title: [Obsessive-compulsive disorders in adolescents with diagnosed schizophrenia].
abstract: The aim of the study was to assess the prevalence of OCD among 200 outpatients and inpatients (102 girls and 88 boys), 15-19 years old (mean age = 17.1 +/- 0.29) with schizophrenia (DSM-III-R, DSM-IV) and to determinate the time of onset of OCD: at least 6 months before schizophrenic symptoms, together with schizophrenic symptoms, while treatment with neuroleptics (name of drug, doses, duration of pharmacotherapy). Patients were examined with SCID-P for DSM-III-R and DSM-IV, version for patient, Y-BOCS and a specially prepared questionnaire for determining the age of onset, duration of OCD and a clinical picture of OCD. OCD was diagnosed in 13% adolescent patients with schizophrenia. Primary OCD--before schizophrenic symptoms was noted in 2.0% of patients, OCD together with schizophrenic symptoms in 4.5% of subjects, and while pharmacotherapy with various atypical neuroleptics: clozapine, risperidone, olanzapine in 6.0% of young patients. The most of assessed patients received clozapine (35 subjects), 24 subjects were treated with risperidone and 17 patients with olanzapine. It was determined that 14.3% of subjects used clozapine, 12.5% of subjects treated with risperidone and 5.9% treated with olanzapine presented OCD, where symptoms had appeared while in pharmacotherapy with these atypical neuroleptics. The differences were not statistically significant. OCD was not observed in these patients who had earlier treatment with classical neuroleptics (for example: haloperidol, perazine). It is possible that part of OCD in schizophrenic patients is induced by medication with new atypical neuroleptics, their influence on serotoninergic system, other, maybe the partial symptomatology of schizophrenia in a special subgroup of patients.
authors.affiliation: II Kliniki Psychiatrycznej Katedry Psychiatrii AM w Łodzi.
authors.forename: J
authors.initials: J
authors.lastname: Rabe-Jabłońska
mesh_terms: D000293:Adolescent; D017668:Age of Onset; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001569:Benzodiazepines; D003024:Clozapine / Q000008:administration & dosage; D015897:Comorbidity; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy / Q000453:epidemiology*; D000077152:Olanzapine; D010890:Pirenzepine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011044:Poland / Q000453:epidemiology; D015995:Prevalence; D018967:Risperidone / Q000008:administration & dosage; D012559:Schizophrenia / Q000139:chemically induced / Q000453:epidemiology*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D003024:Clozapine; D006220:Haloperidol; D018967:Risperidone; D000077152:Olanzapine